Higher-dose dabigatran reduced stroke, but not major hemorrhage, more than warfarin in atrial fibrillation

Klein, Liviu
January 2010
ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p1
Academic Journal
The article discusses a study conducted by researcher S.J. Connolly and colleagues to know whether dabigatran is noninferior to warfarin for reducing stroke and systemic embolism in patients with atrial fibrillation (AF). A randomized, controlled, noninferiority trial at 951 clinical sites in 44 countries was conducted for the study. The study found that dabigatran, if taken 150 mg twice daily, reduces risk for stroke or systemic embolism more than warfarin.


Related Articles

  • Apixaban trial results look promising. Elliott, William T. // Neurology Alert;Oct2011 Clinical Briefs, p1 

    The article discusses the results of the ARISTOTLE trial with the use of apixaban for the prevention of stroke in patients with atrial fibrillation (AF). The ARISTOTLE trial had a primary outcome of ischemic or hemorrhagic stroke, or systemic embolism. After median follow-up, the primary outcome...

  • 2009 - Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. Sobieraj-Teague, Magdalena; Eikelboom, John; Holmes, D. R. // ACP Journal Club;11/17/2009, Vol. 151 Issue 5, p8 

    The article presents information about a clinical trial which analyzes whether percutaneous closure of the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation, is equal to warfarin for preventing stroke. The study involved 707 patients of 18 years of age. The results...

  • 52nd Scientific Session of the American College of Cardiology (ACC): Chicago, USA, March 29--April 1 2003. Purcell, Henry // Current Medical Literature: Interventional Cardiology Monitor;2003, Vol. 10 Issue 2, p35 

    Presents the 52nd scientific session of the American College of Cardiology which focuses on role of thrombin inhibitor in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation. Clinical trials of the inhibitor; Association of drug interactions with...

  • An Alternative to Warfarin Therapy for Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;Oct2009, Vol. 28 Issue 10, p75 

    The article discusses the study "Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomized Non-Inferiority Trial." It performed a randomized trial to compare the efficacy and safety of percutaneous...

  • Ximelagatran effective in preventing stroke in a nonvalvular atrial fibrillation.  // Journal of Family Practice;Apr2004, Vol. 53 Issue 4, p262 

    Presents answers to a question "Is ximelagatran as effective as warfarin in preventing stroke for patients with nonvalvular atrial fibrillation?". In a manufacturer-sponsored, open-label study, patients with atrial fibrillation and at increased risk for stroke treated with either ximelagatran or...

  • Effect of Ximelagatran and Warfarin on Stroke Subtypes in Atrial Fibrillation. Teitelbaum, Jeanne S.; von Kummer, RĂ¼diger; Gjesdal, Knut; Kristinsson, Arni; Gahn, Georg; Albers, Gregory W. // Canadian Journal of Neurological Sciences;May2008, Vol. 35 Issue 2, p160 

    Background and Purpose: The most common stroke subtype among atrial fibrillation (AF) patients not receiving anticoagulants is cardioembolic. In the SPORTIF III and V trials, the oral direct thrombin inhibitor ximelagatran was as effective as warfarin in reducing the risk of stroke in patients...

  • Warfarin vs Clopidogrel Plus Aspirin for Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;Jan2008, Vol. 27 Issue 1, p4 

    The atrial fibrillation clopidogrel trial with Irbesartan for Prevention of Vascular Events (ACTIVE W) is a noninferiority trial comparing anticoagulation with warfarin to therapy with aspirin plus clopidogrel for stroke prevention in patients with atrial fibrillation. ACTIVE W enrolled 6706...

  • Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Oldgren, Jonas; Alings, Marco; Darius, Harald; Diener, Hans-Christoph; Eikelboom, John; Ezekowitz, Michael D.; Kamensky, Gabriel; Reilly, Paul A.; Sean Yang; Yusuf, Salim; Wallentin, Lars; Connolly, Stuart J. // Annals of Internal Medicine;11/15/2011, Vol. 155 Issue 10, p660 

    Background: CHADS2 is a simple, validated risk score for predicting the risk for stroke in patients with atrial fibrillation not treated with anticoagulants. There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS2 score in patients receiving...

  • Warfarin under-used as a stroke prophylaxis. Alexander, Sidney // Modern Medicine;Jun98, Vol. 66 Issue 6, p59 

    Presents an abstract of the article `Screening for Atrial Fibrillation in Primary Care,' by N.M. Wheeldon, D.I. Tayler, et al from the `Heart' journal dated January 1998.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics